Anteris Technologies Global Corp. AVR R2KR3KPHARMA
Company Overview
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -11.2%.
- 5-Year Trend Long-term compounding — revenue CAGR -31.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -31.51% |
| 1 Year: | -11.20% |
Stock Price Performance
| 1 Year: | +122.66% |
| 6 Months: | +45.81% |
| 3 Months: | -6.22% |
| 1 Month: | +8.13% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)53.58 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -31.5% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AVR Anteris Technologies Global Corp. R2KR3KPHARMA | 9.04 | -4.07 | $879.97M | 0.00% | - | -59.21% | -31.51% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 766.00K | 632.00K | 768.98K | - | - | - | - |
| Cost of Revenue | - | - | 443.55K | - | - | - | - |
| Gross Profit | - | - | 325.44K | - | - | - | - |
| Operating Expenses | - | - | 20.92M | - | - | - | - |
| Operating Income | -17.79M | -18.47M | -20.60M | - | - | - | - |
| EBITDA | - | - | -21.40M | - | - | - | - |
| Interest Expense | - | - | 11.74K | - | - | - | - |
| Pretax Income | - | - | -21.79M | - | - | - | - |
| Tax Provision | - | - | 0 | - | - | - | - |
| Net Income | -16.35M | -18.71M | -21.86M | - | - | - | - |
| Diluted EPS | -0.91 | -0.98 | -1.07 | -0.61 | -0.58 | -0.62 | -0.28 |
| R&D Expense | 11.56M | 12.63M | 13.95M | 16.46M | 16.34M | 16.81M | 17.46M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.83M | 3.20M | 2.73M | - | - |
| Cost of Revenue | 3.93M | 2.90M | 1.86M | - | - |
| Gross Profit | 1.91M | 298.38K | 876.80K | - | - |
| Operating Expenses | 18.23M | 31.79M | 47.53M | - | - |
| Operating Income | -16.32M | -31.49M | -46.66M | - | - |
| EBITDA | -15.50M | -29.14M | -45.54M | - | - |
| Interest Expense | 1.03M | 648.71K | 67.09K | - | - |
| Pretax Income | -17.17M | -30.56M | -46.76M | - | - |
| Tax Provision | 0 | 0 | 0 | - | - |
| Net Income | -17.17M | -30.56M | -46.02M | - | - |
| Diluted EPS | - | -2.26 | -2.94 | -3.77 | -2.55 |
| R&D Expense | - | - | - | 51.45M | 69.12M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | 21.43M | 15.99M | 30.53M | 80.70M | 23.00M |
| Current Assets | 18.75M | 12.24M | 24.22M | - | - |
| Cash & Equivalents | 15.46M | 9.29M | 21.03M | - | - |
| Inventory | 549.82K | 355.62K | 442.35K | - | - |
| Receivables | 204.99K | 440.93K | 407.56K | - | - |
| Total Liabilities | 10.91M | 6.95M | 11.63M | 18.02M | 23.25M |
| Current Liabilities | 10.20M | 6.05M | 9.46M | 16.56M | 21.37M |
| Long Term Debt | - | - | 93.84K | - | - |
| Total Debt | 4.14M | 952.79K | 1.69M | - | - |
| Total Equity | 10.52M | 9.03M | 19.30M | 62.76M | -93.00K |
| Shares Outstanding | 35.94M | 35.94M | 35.94M | - | - |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -14.44M | -29.42M | -34.63M | -61.24M | -77.80M |
| Investing Cash Flow | -886.07K | -992.57K | -2.58M | -2.28M | -596.00K |
| Financing Cash Flow | 27.42M | 23.27M | 49.34M | 112.83M | 20.55M |
| Capital Expenditure | -582.24K | -1.67M | -2.39M | -2.27M | -1.95M |
| Free Cash Flow | -15.02M | -31.08M | -37.03M | -63.51M | -79.76M |
| Net Change in Cash | 12.09M | -7.14M | 12.13M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | 32.7% | 9.3% | 32.1% | - | - |
| Operating Margin % | -279.9% | -983.8% | -1,706.0% | - | - |
| Net Margin % | -294.5% | -954.9% | -1,682.8% | - | - |
| ROE % | -163.1% | -338.3% | -238.4% | - | - |
| ROCE % | -145.2% | -316.8% | -221.4% | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | L1 Capital Pty Ltd | 7.99% | 7.79M | $68.08M |
| 2 | FMR, LLC | 7.05% | 6.87M | $60.03M |
| 3 | Blackrock Inc. | 5.92% | 5.77M | $50.44M |
| 4 | Sio Capital Management, LLC | 5.69% | 5.55M | $48.47M |
| 5 | Perceptive Advisors Llc | 3.51% | 3.43M | $29.94M |
| 6 | Nantahala Capital Management, LLC | 3.47% | 3.38M | $29.57M |
| 7 | Adar1 Capital Management, LLC | 3.23% | 3.15M | $27.49M |
| 8 | RA Capital Management, L.P. | 3.08% | 3.00M | $26.22M |
| 9 | BVF Inc. | 3.08% | 3.00M | $26.22M |
| 10 | Ensign Peak Advisors, Inc | 2.45% | 2.39M | $20.89M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AVR
(AVR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxQZjJQUVVJU2JVTlRaQzFhbl9PSmdmTUFmOGo4MF9xR243X3hOQmxwbzZrS2xwMVlhV1k5U05YLVpuNVhVMkZfN0tiUGdkSk9fd2ZHQWFSR1M4amo1MVBvQ0k2aVJWNUR0OHlvbENkNlZybmdyY1V2aW13Q0lqWDN5ak9sLUNMbnVNUkx4Yl…
L1 Capital sells 7,800 Anteris shares at $8.83 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPTkdUcVM3eUd5d0FSTW9QaXFEMDZFYXh6eFpidzhTdnZmbW1mTHhIUWsxQmhyYU41OXdYRWNDUkEtQ3ZtMF9VSmltTV9WX2FlU1U3bFgwd0t1S21ZaHo5VUVSUmpHYmpldEVmREtXZFVaZ2hpNldfbUpkX1MzdjF5YUdrd1V4TGIzc2NuTk…
Should I Buy AVR? AVR 2026 Analysis - Intellectia AI™ - Intellectia AI
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTFA4M3dBaWpMUUR5M1ctWDVRQW5kZFg4OG4wMnh4S0NnT3FIeFdFSlM5eVF6dnFlbHJjUW0ya28xbktCNUcxMGhHeXdZcUVrMVZsSTFNQktJTUtjblpI?oc=5" target="_blank">Should I Buy AVR? AVR 2026 Analysis - Intel…
Insider Sale: 10% owner at $AVR Sells 174,721 Shares - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNdllQVHZlWXNoNFc4RXhadEJNWUZuaGNmbGdXbEFkRG1OQUVFMG1fOWluREZXNlNxVlJBU2FMcDBuVmNsbnltRVBwVmpJRmpMS0NubEcwQ3Z4MzJ1Y0VGanNnQ0FDbE91R3lsVWM2UlZOaEZ6Z1BIcVhZNURINTloWTFleU5mWGpIUjRLdU…
L1 Capital Pty Ltd Sells 7,800 Shares of Anteris Technologies Global Corp. (NASDAQ: AVR) - Kalkine Media
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxORkJHN003ZzNRcHk5ckd0azZYWkUzMUlZOVM0ZUxOSVN0eVJWOVZoczE5bm9qMS1weUg5cUtvWllXZ0lEZTVCMFJpcUJmQjk2M3ozMklkZGVBWmhXaEdxYjJFQXdwZXZGNXZNMXdtZFM3bzVVOUkxWEJOV0ZPcDhpX2xxN0RLQnhIbWdQak…
Anteris Technologies Stock Looks Bullish If DurAVR's PARADIGM Delivers (NASDAQ:AVR) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQYXA1NTE1dWdLRVRieVZzbXFHNjB6WTk4MVNzeW5WaHlIamNaLWxGNHZ4ajZUZFlNN1RpWXJaOXhBVk1kbDBLY0NTdzZBaXRCOUJKXzgxVE9HQ0JaUUs3bWdUci1ZaTJ3RVNGSHpVa3Znd1pVS0JUWTUwMExtVC16bXltTjFCSV9icHRYMj…
AVR — Frequently Asked Questions
What is the current share price of Anteris Technologies Global Corp. (AVR)?
As of 2026-09-07 16:24 PDT, Anteris Technologies Global Corp. (AVR) trades at $9.04 on NasdaqGM. Its 52-week range is $3.38 to $10.57.
What is the market capitalisation of AVR?
Anteris Technologies Global Corp. (AVR) has a market capitalisation of $879.97M on NasdaqGM.
What is the P/E ratio of AVR?
AVR trades at a trailing price-to-earnings (P/E) ratio of -4.07. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.11.
What is the return on equity (ROE) of AVR?
AVR has a return on equity (ROE) of -59.21%.
Is AVR a good stock to buy?
This page provides a data-driven analysis of Anteris Technologies Global Corp. (AVR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.